An2 Therapeutics director Robin Readnour sells $212,701 in common stock
Director Robin Readnour of AN2 Therapeutics Inc. (ANTX) sold 35,402 shares of the company's common stock on August 17, 2026. The shares were divided into two transactions, one for 16,696 shares totaling $100,312 and another for 18,706 shares totaling $112,389. Both sales were executed automatically under Rule 10b5-1 trading plans adopted by MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP.
Following the transactions, MGC 2018 LP and MGC 2018 QP held indirect ownership of 565,592 and 633,867 shares respectively. Mr. Readnour, a member of the company's board of directors and a partner in MGC 2018 GP, LLC, disclaimed beneficial ownership of the sold securities, except for his pecuniary interest. Despite the stock's strong price momentum, analysts rated ANTX with a Strong Buy consensus and a price target of $9, indicating a 51% upside potential.
The company, valued at $225 million, remains unprofitable with an EPS of -$1.04. AN2 Therapeutics recently reported positive results from studies on AN2-502998, an oral treatment for chronic Chagas disease, and received a buy rating from Guggenheim with a price target of $9.00.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
